How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study

References

• International Diabetes FederationDiabetes Atlas Update 20125th edBrussels, BelgiumInternational Diabetes Federation2012
   Google Scholar
• National Kidney FoundationKDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 UpdateAm J Kidney Dis20126085088623067652
   PubMed Web of Science ®Google Scholar
• SharmaSGBombackASRadhakrishnanJThe modern spectrum of renal biopsy findings in patients with diabetesClin J Am Soc Nephrol201381718172423886566
   PubMed Web of Science ®Google Scholar
• JoyceATIacovielloJMNagSEnd-stage renal disease- associated managed care costs among patients with and without diabetesDiabetes Care2004272829283515562193
   PubMed Web of Science ®Google Scholar
• KoroCELeeBHBowlinSJAntidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United StatesClin Ther2009312608261720110005
   PubMed Web of Science ®Google Scholar
• PennoGSoliniABonoraEClinical significance of nonalbuminuric renal impairment in type 2 diabetesJ Hypertens2011291802180921738053
   PubMed Web of Science ®Google Scholar
• RemuzziGSchieppatiARuggenentiPClinical practice. Nephropathy in patients with type 2 diabetesN Engl J Med20023461145115111948275
   PubMed Web of Science ®Google Scholar
• AssogbaGFCouchoudCRoudierCPrevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: The ENTRED surveys (2001 and 2007)Diabetes Metab20123855856623036461
   PubMed Web of Science ®Google Scholar
• MeyersJLCandrilliSDKovacsBType 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustmentPostgrad Med201112313314321566423
   PubMed Web of Science ®Google Scholar
• KDOQIKDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney DiseaseAm J Kidney Dis200749S12S15417276798
   PubMed Web of Science ®Google Scholar
• RigalleauVBeauvieuxMCGonzalezCEstimation of renal function in patients with diabetesDiabetes Metab20113735936621680218
   PubMed Web of Science ®Google Scholar
• EarleyAMiskulinDLambEJLeveyASUhligKEstimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic reviewAnn Intern Med201215678527022312131
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med20083591577158918784090
   PubMed Web of Science ®Google Scholar
• ZoungasSChalmersJDiabetes: glycemic control and outcomes in people with diabetes and CKDNat Rev Nephrol2012813313422310949
   PubMed Web of Science ®Google Scholar
• BonnetFGauthierEGinHExpert consensus on management of diabetic patients with impairment of renal functionDiabetes Metab201137Suppl 2S1S2522108432
   PubMed Web of Science ®Google Scholar
• SlininYIshaniARectorTManagement of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guidelineAm J Kidney Dis20126074776922999165
   PubMed Web of Science ®Google Scholar
• MoenMFZhanMHsuVDFrequency of hypoglycemia and its significance in chronic kidney diseaseClin J Am Soc Nephrol200941121112719423569
   PubMed Web of Science ®Google Scholar
• LipskaKJBaileyCJInzucchiSEUse of metformin in the setting of mild-to-moderate renal insufficiencyDiabetes Care2011341431143721617112
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceType 2 Diabetes: the Management of Type 2 DiabetesNICE clinical guideline 87LondonNational Institute for Health and Clinical Excellence2009 Available from: http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdfAccessed March 21, 2014
   Google Scholar
• VIDAL informationSummary of products characteristics: metformin Available from: http://www.vidal.fr/recherche/index/q:METFORMINE/Accessed April 15, 2014
   Google Scholar
• DruetCBourdel-MarchassonIWeillAType 2 diabetes in France: epidemiology, trends of medical care, social and economic burdenPresse Med201342830838 French23566620
   PubMed Web of Science ®Google Scholar
• BoueeSGaudinAFAmelineauEBonnetFHypoglycemic treatment in type 2 diabetes patients suffering from moderate to severe renal failure in France. Aim of the studyTherapie2013681926 French23484656
   PubMed Web of Science ®Google Scholar
• GrandfilsNDetournayBAttaliCGlucose lowering therapeutic strategies for type 2 diabetic patients with chronic kidney disease in primary care setting in france: a cross-sectional studyInt J Endocrinol2013201364063223653644
   PubMed Web of Science ®Google Scholar
• ShurrawSHemmelgarnBLinMAssociation between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort studyArch Intern Med20111711920192722123800
   PubMedGoogle Scholar
• HolsteinAStumvollMContraindications can damage your health – is metformin a case in point?Diabetologia2005482454245916283245
   PubMed Web of Science ®Google Scholar
• NyeHJHerringtonWGMetformin: the safest hypoglycaemic agent in chronic kidney disease?Nephron Clin Pract2011118c380c38321325870
   PubMed Web of Science ®Google Scholar
• KajbafFArnoutsPdeBMLalauJDMetformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the worldPharmacoepidemiol Drug Saf2013221027103523960029
   PubMed Web of Science ®Google Scholar
• RousselRTravertFPasquetBMetformin use and mortality among patients with diabetes and atherothrombosisArch Intern Med20101701892189921098347
   PubMed Web of Science ®Google Scholar
• EkstromNSchiolerLSvenssonAMEffectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes RegisterBMJ Open201224pii: e001076
   Web of Science ®Google Scholar
• SoliniAPennoGBonoraEDiverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicentre studyDiabetes Care201235114314922124714
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care2012351364137922517736
   PubMed Web of Science ®Google Scholar
• GerichJEMeyerCWoerleHJStumvollMRenal gluconeogenesis: its importance in human glucose homeostasisDiabetes Care20012438239111213896
   PubMed Web of Science ®Google Scholar
• DejagerSSchweizerAIncretin therapies in the management of patients with type 2 diabetes mellitus and renal impairmentHosp Pract (1995)20124072122615074
   PubMedGoogle Scholar
• HungAMRoumieCLGreevyRAComparative effectiveness of incident oral antidiabetic drugs on kidney functionKidney Int20128169870622258320
   PubMed Web of Science ®Google Scholar
• PornetCBourdel-MarchassonILecomtePTrends in the quality of care for elderly people with type 2 diabetes: the need for improvements in safety and quality (the 2001 and 2007 ENTRED Surveys)Diabetes Metab20113715216121435929
   PubMed Web of Science ®Google Scholar
• SoliniAPennoGBonoraEAge, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter StudyJ Am Geriatr Soc2013611253126123889588
   PubMed Web of Science ®Google Scholar
• JohansenOEBirkelandKIDefining the role of repaglinide in the management of type 2 diabetes mellitus: a reviewAm J Cardiovasc Drugs2007731933517953471
   PubMed Web of Science ®Google Scholar
• SchumacherSAbbasiIWeiseDSingle- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairmentEur J Clin Pharmacol20015714715211417447
   PubMed Web of Science ®Google Scholar
• BolenSFeldmanLVassyJSystematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitusAnn Intern Med200714738639917638715
   PubMed Web of Science ®Google Scholar
• PhungOJScholleJMTalwarMColemanCIEffect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetesJAMA20103031410141820388897
   PubMed Web of Science ®Google Scholar
• HasslacherCSafety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal functionDiabetes Care20032688689112610054
   PubMed Web of Science ®Google Scholar
• KothnyWShaoQGroopPHLukashevichVOne-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairmentDiabetes Obes Metab201214111032103922690943
   PubMed Web of Science ®Google Scholar
• LukashevichVSchweizerAShaoQGroopPHKothnyWSafety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trialDiabetes Obes Metab20111394795421733061
   PubMed Web of Science ®Google Scholar
• LukashevichVSchweizerAFoleyJEDickinsonSGroopPHKothnyWEfficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairmentVasc Health Risk Manag20139212823378769
   PubMedGoogle Scholar
• SchweizerADejagerSExperience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairmentDiabetes Ther2013425726723821355
   PubMed Web of Science ®Google Scholar
• Arjona FerreiraJCMarreMBarzilaiNEfficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiencyDiabetes Care2013361067107323248197
   PubMed Web of Science ®Google Scholar
• ChanJCScottRArjona FerreiraJCSafety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyDiabetes Obes Metab20081054555518518892
   PubMed Web of Science ®Google Scholar
• NowickiMRychlikIHallerHLong-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety studyInt J Clin Pract2011651230123921977965
   PubMed Web of Science ®Google Scholar
• McGillJBSloanLNewmanJLong-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled studyDiabetes Care20133623724423033241
   PubMed Web of Science ®Google Scholar
• GroopPHCooperMEPerkovicVEmserAWoerleHJvonEMLinagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunctionDiabetes Care2013363460346824026560
   PubMed Web of Science ®Google Scholar
• HaluzikMFrolikJRychlikIRenal effects of DPP-4 inhibitors: a focus on microalbuminuriaInt J Endocrinol2013201389510224089613
   PubMed Web of Science ®Google Scholar
• ManciaGFagardRGuidelines for the management of hypertension and target organ damageJ Hypertens2013312464246524220597
   PubMed Web of Science ®Google Scholar
• KrauseTLovibondKCaulfieldMMcCormackTWilliamsBManagement of hypertension: summary of NICE guidanceBMJ2011343d489121868454
   PubMed Web of Science ®Google Scholar
• de ZeeuwDThe end of dual therapy with renin-angiotensin-aldosterone system blockade?N Engl J Med20133691960196224206456
   PubMed Web of Science ®Google Scholar
• DetournayBSimonDGuillausseauPJChronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetesDiabetes Metab201238210211222252014
   PubMed Web of Science ®Google Scholar